Další formáty:
BibTeX
LaTeX
RIS
@article{1776197, author = {Hubacek, Jaroslav A. and Dušek, Ladislav and Májek, Ondřej and Adamek, Vaclav and Cervinkova, Tereza and Dlouha, Dana and Pavel, Jozef and Adamkova, Vera}, article_location = {Praha}, article_number = {1}, doi = {http://dx.doi.org/10.33549/physiolres.934647}, keywords = {COVID-19; CCR5; Polymorphism; Deletion; Delta 32}, language = {eng}, issn = {0862-8408}, journal = {Physiological research}, title = {CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects}, url = {https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf}, volume = {70}, year = {2021} }
TY - JOUR ID - 1776197 AU - Hubacek, Jaroslav A. - Dušek, Ladislav - Májek, Ondřej - Adamek, Vaclav - Cervinkova, Tereza - Dlouha, Dana - Pavel, Jozef - Adamkova, Vera PY - 2021 TI - CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects JF - Physiological research VL - 70 IS - 1 SP - 111-115 EP - 111-115 PB - Fyziologický ústav AV ČR SN - 08628408 KW - COVID-19 KW - CCR5 KW - Polymorphism KW - Deletion KW - Delta 32 UR - https://www.biomed.cas.cz/physiolres/pdf/2021/70_111.pdf N2 - Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), has spread widely around the globe. Significant inter-individual differences have been observed during the course of the infection, which suggests that genetic susceptibility may be a contributing factor. CC chemokine receptor 5 (CCR5), which acts as a co-receptor for the entry of HIV-1 into cells, is promising candidate whose can have an influence on SARS-CoV-2 infection. A genetic mutation known as CCR5 Delta 32, consisting of a 32-nucleotide deletion, encodes a truncated protein that protects homozygous carriers of the deletion from HIV-1 infection. Similarly, inhibition of CCR5 seems to be protective against COVID-19. In our study, we successfully genotyped 416 first-wave SARS-CoV-2-positive infection survivors (164 asymptomatic and 252 symptomatic) for CCR5 Delta 32, comparing them with a population based sample of 2,404 subjects. We found the highest number (P=0.03) of CCR5 Delta 32 carriers in SARS-CoV-2-positive/COVID-19-asymptomatic subjects (23.8 %) and the lowest number in SARS-CoV-2-positive/COVID-19-symptomatic patients (16.7 %), with frequency in the control population in the middle (21.0 %). We conclude that the CCR5 Delta 32 I/D polymorphism may have the potential to predict the severity of SARS-CoV-2 infection. ER -
HUBACEK, Jaroslav A., Ladislav DUŠEK, Ondřej MÁJEK, Vaclav ADAMEK, Tereza CERVINKOVA, Dana DLOUHA, Jozef PAVEL a Vera ADAMKOVA. CCR5 Delta 32 Deletion as a Protective Factor in Czech First-Wave COVID-19 Subjects. \textit{Physiological research}. Praha: Fyziologický ústav AV ČR, 2021, roč.~70, č.~1, s.~111-115. ISSN~0862-8408. Dostupné z: https://dx.doi.org/10.33549/physiolres.934647.
|